



CLINICAL INSIGHTS

EXCEL Division of Blue Cross Laboratories

ANGICAM TABLET

Issue II, No.5, 2025

Amlodipine versus nifedipine for the management of postpartum hypertension: a non-inferiority randomized controlled trial

Pratt K, et.al; Am J Obstet Gynecol MFM. 2025 Jan;7(1):101575.

- Postpartum hypertension is an increasingly prevalent problem and optimizing its treatment is imperative in reducing maternal morbidity and improving long-term health outcomes. Despite this, data on treatment of postpartum hypertension is limited.
- The objective of this randomized controlled study in 132 subjects was to evaluate the use of amlodipine for the treatment of postpartum hypertension.
- There were no differences in use of additional antihypertensives or patient-reported side effects or breastfeeding outcomes, but hypotension and tachycardia were less common with amlodipine use.
- Amlodipine was significantly less likely to be discontinued due to side effects.

Amlodipine is non-inferior to nifedipine for postpartum hypertension treatment & the rates of side effects were similar between groups, but there was a statistically significant difference in discontinuation rates with lesser rates in Amlodipine group.

